Prevalence of erm methylase genes in clinical isolates of non-pigmented, rapidly growing mycobacteria

Clinical Microbiology and Infection

Volumn 15, Issue 10, 2009, Pages 919-923

  Esteban, J ^a   Martin de Hijas N Z ^a   Garcia Almeida D ^a   Bodas Sánchez, Á ^b   Gadea, I ^a   Fernandez Roblas R ^a  

^a Department of Clinical Microbiology ^*  (Spain)

^b Unilabs   (France)

Author keywords

Clarithromycin; Erithromycin; Inducible; Methylases; PCR

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ERM METHYLASE; ERYTHROMYCIN; METHYLTRANSFERASE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; GENE FREQUENCY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM; MYCOBACTERIUM MAGERITENSE; MYCOBACTERIUM MUCOGENICUM; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; SPECIES DIFFERENCE; STRAIN DIFFERENCE;

CORYNEBACTERINEAE; MYCOBACTERIUM MAGERITENSE; MYCOBACTERIUM MUCOGENICUM;

EID: 70350600578     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.02757.x     Document Type: Article

References (16)

1. Diagnosis and treatment of disease caused by non-tuberculous mycobacteria. Am J Respir Crit Care Med 1997, 156 (suppl):S1-S25.
2. Brown-Elliott BA, Wallace RJ. Clinical and taxonomic status of pathogenic non-pigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 2002, 15:716-746.
3. De Groote MA, Huitt G. Infections due to rapidly growing mycobacteria. Clin Infect Dis 2006, 42:1756-1763.
4. Wallace RJ. Treatment of infections caused by rapidly growing mycobacteria in the era of the newer macrolides. Res Microbiol 1996, 147:30-35.
5. Tartaglione T. Treatment of non-tuberculous mycobacterial infections: role of clarithromycin and azithromycin. Clin Ther 1997, 19:626-638. discussion 603
6. Driscoll MS, Tyring SK. Development of resistance to clarithromycin after treatment of cutaneous Mycobacterium chelonae infection. J Am Acad Dermatol 1997, 36:495-496.
7. Vemulapalli RK, Cantey JR, Steed LL, Knapp TL, Thielman NM. Emergence of resistance to clarithromycin during treatment of disseminated cutaneous Mycobacterium chelonae infection: case report and literature review. J Infect 2001, 43:163-168.
8. Tebas P, Sultan F, Wallace RJ, Fraser V. Rapid development of resistance to clarithromycin following monotherapy for disseminated Mycobacterium chelonae infection in a heart transplant patient. Clin Infect Dis 1995, 20:443-444.
9. Nash KA, Andini N, Zhang Y, Brown-Elliott BA, Wallace RJ. Intrinsic macrolide resistance in rapidly growing mycobacteria. Antimicrob Agents Chemother 2006, 50:3476-3478.
10. Stutcliffe J, Grebe T, Tait-Kamradt A, Wondrack L. Detection of erythromycin-resistant determinants by PCR. Antimicrob Agents Chemother 1996, 40:2562-2566.
11. Buriankova K, Doucet-Populaire F, Dorson O, Gondran A, Ghnassia JC, Weiser J. Molecular basis of intrinsic macrolide resistance in the Mycobacterium tuberculosis complex. Antimicrob Agents Chemother 2004, 48:143-150.
12. Andini N, Nash KA. Intrinsic macrolide resistance of the Mycobacterium tuberculosis complex is inducible. Antimicrob Agents Chemother 2006, 50:2560-2562.
13. Esteban J, Fernandez Roblas R, Garcia Cia JI, Zamora N, Ortiz A. Clinical significance and epidemiology of non-pigmented rapidly growing mycobacteria in a university hospital. J Infect 2007, 54:135-145.
14. Costerton JW. The Biofilm Primer 2007, 180. 1st edn, Berlin, Springer-Verlag
15. van Griethuysen A, van Loo I, van Belkum A, Vandenbroucke-Grauls C, Wannet W, van Keulen P. Loss of the mecA gene during storage of methicillin-resistant Staphylococcus aureus strains. J Clin Microbiol 2005, 43:1361-1365.
16. Robert MC. Distribution of macrolide, lincosamide, streptogramin, ketolide and oxazolidinones (MLSKO) resistance genes in Gram-negative bacteria. Curr Drug Targets Infect Disord 2004, 4:207-215.